| Cas No.: | 156177-65-0 | 
| Chemical Name: | methyl (5R,7R,8S)-2,11-bis((ethylthio)methyl)-7-hydroxy-15-oxo-5,6,7,8,14,15-hexahydro-13H-16-oxa-4b,8a,14-triaza-5,8-methanodibenzo[b,h]cycloocta[jkl]cyclopenta[e]-as-indacene-7-carboxylate | 
| Synonyms: | KT-7515;KT 7515;CEP 1347 | 
| Formula: | C33H33N3O5S2 | 
| M.Wt: | 615.76 | 
| Purity: | >98% | 
| Sotrage: | 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO | 
| Description: | CEP-1347 (KT-7515) is a potent and selective MLK inhibitor that completely rescues motoneurons and inhibits JNK1 activation with IC50 of 20 nM; has weak inhibitory activity for Trk A and MLCK; promotes motoneuron survival and simultaneously inhibits the JNK1 signaling cascade; inhibits recombinant MLK1/2/3 with IC50 of 23-51 nM; blocks cell death (overexpression of MLK3) in CHO cells; elicits neuroprotective and anti-inflammatory responses in models of neurodegenerative diseases. Parkinson Disease Phase 2 Discontinued | 

To enhance service speed and avoid tariff delays, we've opened a US warehouse. All US orders ship directly from our US facility.
            